Variable | Frequency | Percent (%) | |
---|---|---|---|
ART eligibility criteria | |||
WHO clinical stage | 9 | 1.6 | |
Immunological/CD4Count | 35 | 6.4 | |
Both clinical and immunologic | 505 | 92.0 | |
Type of drug at initiation of therapy | |||
4a(d4T-3TC-NVP) | 208 | 37.9 | |
4b(d4T-3TC-EFV) | 37 | 6.7 | |
4c(AZT-3TC-NVP) | 258 | 47.0 | |
4d(AZT-3TC-EFV) | 43 | 7.8 | |
Kaletra based | 3 | 0.6 | |
Regimen change during follow up | |||
Yes | 68 | 12.5 | |
No | 475 | 87.5 | |
Absolute CD4 count | |||
CD4 count below the threshold | 289 | 52.6 | |
CD4 count above the threshold | 260 | 47.4 | |
Developmental History | |||
Appropriate | 531 | 96.7 | |
Delayed | 9 | 1.6 | |
Regressing | 9 | 1.6 | |
Cotrimoxazole preventive therapy | |||
Yes | 287 | 52.3 | |
No | 262 | 47.7 | |
Nutritional status | |||
Underweight | 453 | 82.5 | |
Normal | 92 | 16.8 | |
Overweight | 4 | 0.7 | |
WHO clinical staging | |||
I | 45 | 8.2 | |
II | 128 | 23.3 | |
III | 317 | 57.7 | |
IV | 59 | 10.7 | |
Haemoglobin(520) | |||
<10gm/dl | 103 | 19.8 | |
≥10gm/dl | 417 | 80.2 | |
3 rd month ART drug adherence (497) | |||
Good | 491 | 98.8 | |
Fair | 3 | 0.6 | |
Poor | 3 | 0.6 | |
OIs during follow up | |||
Yes | 165 | 30.1 | |
No | 384 | 69.9 | |
Side effect during follow up(526) | |||
Yes | 49 | 8.9 | |
No | 477 | 86.9 |